Glioblastoma (GBM) is the most aggressive and fatal brain cancer, with a median survival of just 15 months.
We have developed a dual-action CAR-T cell therapy for GBM, targeting the tumor directly while secreting a CD47-blocker to reprogram macrophages and mount a coordinated immune attack against the tumor.
With our therapy, we expect increased survival rates and significantly reduced side effects compared to standard-of-care treatments and other new product developments (e.g. ADCs).
Our program is on track for IMPD submission and first-in-human (FIH) clinical trial initiation in 2026.
The company is a spin-off from University of Basel.
Founders:
Prof. Dr. Gregor Hutter (CMO),
Dr. Patrice Zeis (COO),
Dr. Valerio Sabatino (CSO),
Dieter Willmann (CEO)
News
Milestones/News
